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Background: Resection of gastrointestinal (GI) metastases of malignant melanoma (MM) offers a sig-
niﬁcant survival beneﬁt. No adjuvant therapy has been shown to be effective in the treatment of these
metastases.
Methods: All resections of MM affecting the GI tract at a UK University teaching hospital between
October 1999 and January 2013 were identiﬁed from a pathology database. Demographic, investigative,
operative and outcome data were retrieved from hospital records. Survival analysis was performed.
Results: Thirty patients were identiﬁed (median age 62.7 years). 3 patients underwent a second oper-
ation at a later date to resect further metastases. 6 patients (20.0%) presented with no identiﬁable
cutaneous lesion. The average time to GI metastases was 52.0 months (range 4.9e139.8 months) for
those with an identiﬁed cutaneous primary (n ¼ 24). Two patients with initial cutaneous lesions with
Breslow’s thickness <1 mm developed GI metastases.
Common presenting symptoms included abdominal pain (n ¼ 8, 27.6%), GI bleeding (n ¼ 5, 17.2%) and
symptoms of GI tract obstruction (n ¼ 4, 13.8%). CT scan was the most commonly performed investigation
(96.6%). Over half of resections (54.5%, n ¼ 18) included small bowel resection. Mortality at 2 and 5 years
was 66.4% and 73.1%. Of the 3 patients who underwent a second resection of GI metastases, one is still
alive after 26 months of follow up; 2 patients died after 32.8 and 18.6 months.
Conclusions: Clinicians should have a low threshold for investigating GI symptoms in patients with a
history of malignant melanoma even in the case of early-stage primary disease. Re-resection should be
considered in patients presenting with further GI metastases.
Crown Copyright  2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd. All rights
reserved.1. Background
Melanoma is the most common tumour to metastasise to the
gastro-intestinal (GI) tract. These tumours are commonly metas-
tases from a cutaneous or less frequently, an ocular primary lesion.
Rarely malignant melanomas (MM) of the GI tract can be primary
tumours.
The superﬁcial spreading sub-type of MM is most likely to
metastasise to small intestine although all are capable of such
spread [1]. Amersi and colleagues implicated chemokine receptor-9
(CCR9), which contributes to enhanced motility of melanoma cells,
and its ligand CCL25 in the preferential metastasis of MM to this
location [2].l Surgery, Queen Elizabeth
irmingham B15 2WB, UK.
atel).
evier Ltd on behalf of Surgical AssoThe existence of primary intestinal melanoma remains a
contentious subject with some authors stating the aetiology of GI
tract MM as unknown or regressed primary lesions. Plausible the-
ories attribute the origins of primary melanoma of the small in-
testine to schwannian neuroblast cells [3], melanoblastic cells of
the neural crest [4], or amine-precursor uptake and decarboxyl-
ation (APUD) cells via neoplastic transformation [5].
Up to 60% of patients with MM will have evidence of GI me-
tastases at autopsy yet only 1e4% of all patients with MMwill have
clinical manifestations of GI tract involvement during their lifetime
[6].
Acute presentations include intestinal obstruction (including
intussusception [7]), massive GI haemorrhage and less commonly,
perforation. Sub-acute presentation commonly includes symptoms
of anaemia (including occult GI haemorrhage), cramping/chronic
abdominal pain and an abdominal mass [8]. Less frequent pre-
sentations include obstructive jaundice caused by obstructing le-
sions within the biliary tree [9].ciates Ltd. All rights reserved.
Table 1
Demographic details of cohort, initial melanoma, investigation and operative re-
sections performed.
n ¼ 30 %
Gender Male 22 73.3
Female 8 26.7
Age <50 9 30.0
>50 21 70.0
Primary cutaneous lesion Identiﬁed 24 80.0
GI tract ﬁrst presentation of
disease
6 20.0
n ¼ 24 %




n ¼ 19 %




n ¼ 22 %
a,b
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ORIGINAL RESEARCHStandard CT scan is commonly used to locate MM spread intra-
abdominally although 18F-2-ﬂuoro-2-deoxy-D-glucose-positron
emission tomography (FDG PET) CT scan has been shown to have a
higher sensitivity and accuracy in the detection of visceral metas-
tases, including extra-intestinal metastatic disease [10,11]. Con-
ventional endoscopy for proximal and distal portions of the GI tract
offers the possibility of biopsy. Less readily available capsule
endoscopy allows non-invasive examination of the small bowel
mucosa although difﬁculties exist in locating lesions and an
inability to biopsy lesions.
Systemic chemotherapy regimens show no beneﬁt to overall
survival and are not recommended for treatment of GI tract me-
tastases of MM [12]. Surgery is carried out for acute intra-
abdominal emergency such as obstruction or haemorrhage, yet
the criteria for surgery in minimally symptomatic/asymptomatic
metastases is less well deﬁned.
Most case series for GI tract metastases of MM have come from
Australia and US populations. We therefore undertook an analysis
of all resections for MM GI tract metastases at a large university
teaching hospital in the UK to see if some common conclusions
could be drawn.Presenting symptoms Pain 8 27.6
GI bleeding 5 17.2
GI tract obstruction 4 13.8
Anaemia 2 6.9
Abdominal mass 2 6.9
Altered bowel habit 2 6.9
Abdominal distension 1 3.4
Jaundice 1 3.4
Asymptomatic 7 24.1
n ¼ 29 %
Investigationsc CT scan 28 96.6




n ¼ 29 %
Extra-GI metastasesa Present 20 69.0
Absent 9 31.0
n ¼ 33 %
Operation Small bowel resection alone 13 39.4
Large bowel resection alone 7 21.2
Small bowel resection and other
visceral resection
3 9.1
Small and large bowel resection 2 6.1
Partial/complete resection of 2 6.12. Methods
A single-centre retrospective review of cases of MM affecting
the GI tract was conducted between October 1999 and January
2013. Our unit’s pathology database was searched for all resections
involving the GI tract, excluding hepatic metastases, with a ﬁnal
diagnosis of malignant melanoma.
Information was collected regarding the primary melanoma
where appropriate including histopathological staging and loca-
tion. Information on GI melanoma was collected including pre-
sentation, investigation, surgical resection(s) and follow up.
Patients were excluded from subsequent analysis if they didn’t
undergo resection of GI metastases.
Patient survival was calculated from the date of GI resection to
date of death. If the patient was still alive according to NHS records,
survival timewas from date of GI resection to date of study analysis.
Survival curves were plotted using SPSS version 19 (IBM Corp.,
Armonk, NY) and signiﬁcant differences between survival curves
was tested using the log-rank ManteleCox test. Internal audit
approval was sought prior to data collection.stomach
Whipple procedure 1 3.0
Other combinations 5 15.2
a Where n is less than 30, information was not available for the remaining
patients.
b Several patients experienced more than one symptom.
c Several patients underwent more than one investigation.3. Results
The 30 patients identiﬁed comprised of 22 males and 8 females
(see Table 1). The median age at operation was 62.7 years (range
24.4e77.6 years). Of the 30 patients, 27 (90.0%) underwent one
operation to resect GI metastases. Three (10.0%) had a second
operation at a later date to resect further GI metastases.
A primary cutaneous lesion was identiﬁed in 24 cases (80.0%)
with the remaining 6 patients (20.0%) presenting with GI tract
involvement as the ﬁrst site of disease. Details of the lymph node
status of the primary lesion were not available. The median time to
GI metastases was 43.0 months (range 4.9e139.8 months) for those
with an identiﬁed cutaneous primary (n ¼ 24). There was a trend
towards increased time to GI metastases with early stage primary
disease but this did not reach statistical signiﬁcance (P ¼ 0.08,
KruskalleWallis, see Table 2).
The most common presenting symptoms were abdominal pain
(n ¼ 8, 27.6%), GI bleeding (n ¼ 5, 17.2%), and GI tract obstruction
(n ¼ 4, 13.8%). Other complaints included an abdominal mass,
symptoms of anaemia and altered bowel habit. Seven patients
(24.1%) did not complain of any symptoms. One patient whopresented with obstructive jaundice secondary to a pancreatic
metastasis went on to have a Whipple’s procedure.
3.1. Imaging
The majority of patients (n ¼ 28, 96.6%) underwent a conven-
tional CT scan. The ﬁve patients (17.2%) whowere imaged with PET-
CTunderwent this investigation in addition to conventional CTscan.
Seven patients (24.1%) were imaged with more than one modality.
3.2. Operative procedures
A total of 33 operative resections were performed resulting in
complete excision of intra-abdominal metastases with clear
Table 2






GI mets, months (IQR)
Median survival time following
resection, months (standard error)
<1 2 120.9 3.0
1.01e2 8 50.4 (32.2) 16.0 (9.3)
2.01e4 8 37.3 (42.5) 13.0 (4.9)
>4 6 36.9 (45.1) 5.0 (0.9)
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ORIGINAL RESEARCHmargins histologically in 90.9% (n ¼ 30). The most commonly
performed operation was small bowel resection alone (n ¼ 13,
39.4%) although over half of all operations (n ¼ 18, 54.5%) incor-
porated a small bowel resection.
Seven large bowel resections were performed (22.6%). These
included one right hemicolectomy, one left hemicolectomy and 5
abdomino-perineal resections. Other combinations included exci-
sion of the omentum alone; resection of a pelvic mass; distal
pancreatectomy with superior mesenteric vein resection, splenec-
tomy and left hemicolectomy; partial gastrectomy and partial
colectomy; and right hemicolectomy with removal of omentum.
The majority of initial operations were carried out as elective
procedures (n ¼ 27, 81.8%) with 6 (24.2%) performed in the emer-
gency setting. Three patients underwent a second resection for GI
metastases at an average of 7.5 months following initial operation
(range 6.3e9.7months). Of these, one is still alive after 26months of
follow-up and 2 patients died after 32.8 months and 18.6 months
respectively. All but 3 resections (9.1%) resulted in complete removal
of the GI metastases but assumptions of curative intent were only
made in the absence of extra-GI disease. 3 patients required a sec-
ond operation in the post-operative period for complications
related to the initial resection: Refashioning of anastomosis after
anastomotic leak following left hemicolectomy (day 8); small bowel
obstruction following small bowel resection (day 7); and refa-
shioning of anastomosis for post-operative bleeding (day 6).3.3. Survival
One patient died 8 days following an abdomino-perineal
resection for rectal metastasis due to a cardiac arrest secondary
to ventricular tachycardia likely due to an ischaemic event. This
patient was excluded from subsequent survival analysis. The esti-
mated 2-year and 5-year survival was 33.6% (mortality 66.4%) andFig. 1. Survival curve for cohort following resection of GI metastasis.26.9% (mortality 73.1%) respectively (see Fig. 1). Survival was
affected by the presence of extra-GI metastases at the time of
resection (see Fig. 2). There was a statistically signiﬁcant difference
between the survival curves for the presence or absence of extra-GI
metastases (P ¼ 0.012). There was no difference in the survival
curves for patient gender (P ¼ 0.148), emergency/elective resection
(P ¼ 0.423) or patient age dichotomized above and below the
median (P ¼ 0.509).
4. Discussion
We have presented data from all patients treated at a large UK
teaching hospital, with MM involvement of the GI tract undergoing
resection, over a period of 14 years. To date, only one similar case
series by Retsas in 2001 [13] has described GI metastases of MM in
19 patients within a UK population of whom 12 underwent surgical
resection. Larger studies have emanated predominantly from
Australia and USA although two European studies have also re-
ported resection of GI metastases [14,15].
In a case series of 117 patients from the Sydney melanoma unit
over a 24 year period [8], limited small bowel resection alone
accounted for 77% of operations with a further 9% of patients un-
derwent small bowel resection as part of MM metastasectomy. In
our study, a slightly lower proportion of patients underwent small
bowel resections (54.5%).
4.1. Demographics
We reported two patients with GI metastases who had prior
primary cutaneous lesions with a Breslow’s thickness of less than
1 mm - considered low risk for the development of metastaticFig. 2. Survival curve for patients with and without extra-GI metastasis at time of
resection.
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metastasectomy had a primary MM Breslow thicknesses <2 mm
[8]. This may be consistent with our data although the Breslow
thickness was not subclassiﬁed beyond <2 mm. Similarly, a US
study reported a Breslow thickness <1.5 mm in 15% of patients
undergoing resection for GI metastases [16]. We were unable to
determine the overall incidence of GI metastases in patients with
cutaneous MM and the number of patients denied surgical resec-
tion, as our centre is a tertiary referral centre, receiving referrals for
metastatic MM from many other hospitals.
In our cohort the time from excision of primary MM to diagnosis
of GI metastases did not vary signiﬁcantly by Breslow’s thickness.
The mean time to GI metastases from primary lesion excision was
less than 4 years, demonstrating an aggressive nature of malignant
melanoma, even in the presence of clear excision margins.
Seven patients, representing approximately one-quarter of the
cohort, were less than 40 years of age at time of resection of GI
metastases. As the incidence of cutaneous melanoma continues to
rise in the UK [17], clinicians also need to exercise suspicion for GI
metastasis in progressively younger age groups.
The GI tract was the ﬁrst site of disease in 20% of patients in our
study; nearly double the 10.2% reported in the study from the
Sydney Melanoma Unit [8]. Our results are however entirely in
keeping with a higher proportion of potential primary GI tract
melanomas reported in a US study [16] and a study from Thailand
[18].
Nearly a quarter of patients (n ¼ 7, 24.1%) did not report any GI
symptoms but were found to have GI metastasis on imaging per-
formed for nodal or extra-GI metastasis. Low morbidity resection
was offered to this group to prevent acute symptoms.
4.2. Imaging
CT scan was the most common imaging modality used to
investigate GI symptoms. Current UK guidelines [19] for the man-
agement of cutaneous melanoma supports the use of whole body
CT imaging as the primary investigation of choice to diagnose stage
IV disease. PET-CT is recommended where metastatectomy is
planned to search for other occult metastases.
4.3. Survival
Surgical resection, in the form of limited small bowel or large
bowel disease, offers the patient both symptomatic and survival
beneﬁt. Even when incompletely resected, surgical treatment is
associated with an improved survival compared with un-resected
metastatic disease [20]. A systematic review and meta-analysis
[21] has also shown an improvement in disease free survival and
overall survival for IFN-alpha therapy. However, heterogeneity of
drug dose and preparation combined with inconsistency in results
of individual RCTs, have resulted in IFN-alpha not being used as a
standard treatment in UK clinical practice. Ipilimumab [22,23] and
Vemurafenib [24] are immunological therapies currently being
evaluated by NICE. However none of the randomized control trials
for these agents speciﬁcally investigate the response of GI disease
or the survival beneﬁt versus surgery.
There is no standardized criteria for operativemanagement of GI
metastases of MM. It has been demonstrated that small bowel
resection is beneﬁcial in treating impending intra-abdominal ca-
tastrophe in established stage IV disease. However, the resection of
GI metastasis in minimally symptomatic or asymptomatic patients
with un-resectable metastases elsewhere, is more contentious.
Thus the decision to operate is dependent on co-morbidities and
extra-GI metastatic burden. However small bowel resection, even
with an open approach, is a relatively low morbidity operation.Emergency surgery has, however, been suggested as a negative
factor for survival [25]. We were unable to demonstrate such an
association in our study, although this may be due to the small
number of cases undergoing emergency resection.
Previous studies have established that resection of MM GI me-
tastases confers a survival advantage [8,26] Our cohort’s 5 year
survival of 26.9% is consistent with reports from the US [25](21%)
and Australia [8] (27%). This was higher than reported elsewhere in
studies from the US [27] (9%) and Poland [14] (17%). The higher
mortality from these latter studies is possibly accounted for by a
lower proportion of patients in our cohort undergoing emergency
[14]. We also demonstrated a signiﬁcant difference in survival by
presence or absence of extra-GI metastases at the time of operation.
Again, this is consistent with the results of others cohorts [8,28].
However, less than a third of our cohort underwent resection of GI
metastases in the absence of extra GI metastatic disease, compared
to 63% in the Australian report.
Our cohort size was small and did not allow for any further
evaluation of possible poor survival risk factors. Three patients had
reasonable survival following second resection of GI metastases;
re-resection has not been considered by other cohorts.5. Concluding remarks
In conclusion, we have demonstrated in a UK population that
resection of GI metastases can achieve prolonged remission, espe-
cially in the absence of extra-GI metastases. Clinicians should have
a low threshold for investigating any GI symptoms regardless of the
staging of the primary lesion. We have reported long survival times
in patients undergoing resection for recurrent MM GI metastases.
We therefore believe that recurrent GI metastases should not be
considered a contraindication to further surgery.
The recent research reporting CCR9 expression on MM GI me-
tastases is intriguing. It is possible to envisage CCR9 phenotyping of
primary MM lesions in the future. CCR9 phenotyping could be used
to identify CCR9 expressing primary tumours which may be suit-
able for more intensive GI imaging as part of their follow-up. In
addition, CCR9 blockade could plausibly prevent the development
of GI metastases.6. What’s new in this paper
Our study in a UK population showed survival following resec-
tion of GI metastases of malignant melanoma was comparable to
US and Australian populations.
Patients with initial cutaneous lesions with <1 mm Breslow
thickness, thought to be low risk for development of metastastic
disease, went on to develop GI metastases.
Three patients had more than one resection associated with
reasonable survival. Therefore, re-resection should be considered.Conﬂict of interest statement
Nil to declare.References
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